Skip to main content

Table 2 Concomitant medications included in the models

From: Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients

Drug Metabolism Concomitant medications taken by study patients Effect† %*
Artemether CYP2B6 ‡ [33, 34]    0%
  CYP2C9‡ [33, 34] Ibuprofen, pyrimethamine and quinine Strong to moderate inhibitor 22%
  CYP2C19‡ [34]    0%
  CYP3A4[3235] Caffeine, doxycycline, erythromycine and metronidazole Moderate inhibitors 10%
  CYP3A5[32, 34]    0%
Dihydroartemisinin Glucuronidation [36] --   
Lumefantrine CYP3A4[32, 35] Caffeine, doxycycline, erythromycine and metronidazole Moderate inhibitors 10%
Mefloquine CYP3A4[3739] Clarithromycine, caffeine, metronidazole and tetracycline Strong to moderate inhibitor 8%
  CYP3A5[37]    0%
Piperaquine Unknown [31] Chloroquine, ibuprofen and quinine Strong to moderate inhibitor of CYP2C8, CYP2C9 and / or CYP2D6 45%
  1. * Percentage of patients in the study taking the respective inhibitor.
  2. † From UpToDate Online 17.1 (http://www.uptodateonline.com/online/index.do).
  3. ‡ Only in vitro, not seen in healthy volunteers [40].